NurExone Announces Further Expansion of ExoPTEN Patent Coverage
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced the expansion of its ExoPTEN patent coverage. The Israel Patent Office issued a Notice of Allowance for a patent titled 'Vesicles Comprising a PTEN Inhibitor and Uses of Same', which covers innovative Extracellular Vesicles (EVs) with a PTEN inhibitor. This patent is important for NurExone's ExoPTEN drug, aimed at promoting nerve growth and regeneration after acute spinal cord injury.
The company also revealed its engagement with Allele Capital Partners, for investor relation services, including capital markets consultation and corporate video dissemination on social media. The initial agreement is for one month at $11,000 per month, with potential for extension and a fee increase to $14,500 upon uplisting to NYSE or NASDAQ.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) ha annunciato l'espansione della sua copertura brevettuale ExoPTEN. L'Ufficio Brevetti di Israele ha emesso un Avviso di Concessione per un brevetto intitolato 'Vesicoli Comprendenti un Inibitore di PTEN e i loro Usi', che copre innovativi Vesicoli Extracellulari (EV) con un inibitore di PTEN. Questo brevetto è importante per il farmaco ExoPTEN di NurExone, mirato a promuovere la crescita e la rigenerazione dei nervi dopo un infortunio acuto del midollo spinale.
La società ha anche rivelato il suo coinvolgimento con Allele Capital Partners, per servizi di relazioni con gli investitori, inclusi consulenza sui mercati dei capitali e diffusione di video aziendali sui social media. L'accordo iniziale è di un mese a $11,000 al mese, con la possibilità di estensione e un aumento della tariffa a $14,500 al momentolisting sulla NYSE o sul NASDAQ.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) ha anunciado la expansión de su cobertura de patente ExoPTEN. La Oficina de Patentes de Israel emitió un Aviso de Aprobación para una patente titulada 'Vesículas que Comprenden un Inhibidor de PTEN y sus Usos', que cubre innovadoras Vesículas Extracelulares (EV) con un inhibidor de PTEN. Esta patente es importante para el medicamento ExoPTEN de NurExone, cuyo objetivo es promover el crecimiento y la regeneración de nervios tras una lesión aguda de la médula espinal.
La empresa también reveló su colaboración con Allele Capital Partners para servicios de relaciones con inversores, que incluyen consultoría de mercados de capital y difusión de videos corporativos en redes sociales. El acuerdo inicial es por un mes a $11,000 al mes, con la posibilidad de extensión y un aumento de la tarifa a $14,500 con la lista en la NYSE o NASDAQ.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF)는 ExoPTEN 특허 범위 확대를 발표했습니다. 이스라엘 특허청은 'PTEN 억제제를 포함하는 소포 및 그 사용'이라는 제목의 특허에 대해 허가 통지를 발부했습니다. 이 특허는 PTEN 억제제를 포함한 혁신적인 세포외 소포(EVs)를 포함하고 있습니다. 이 특허는 NurExone의 ExoPTEN 약물에 중요하며, 이는 급성 척수 손상 이후 신경 성장과 재생을 촉진하는 것을 목표로 하고 있습니다.
회사는 또한 Allele Capital Partners와 약정을 체결하여 투자자 관계 서비스에 참여하고 있으며, 여기에는 자본 시장 상담 및 소셜 미디어에서의 기업 비디오 배포가 포함됩니다. 초기 계약은 한 달 동안 월 $11,000이며, NYSE 또는 NASDAQ에 상장될 경우 연장 및 요금 인상이 $14,500로 증가할 수 있습니다.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) a annoncé l'extension de sa couverture de brevet ExoPTEN. L'Office des Brevets d'Israël a émis un Avis d'Octroi pour un brevet intitulé 'Vésicules Comprenant un Inhibiteur de PTEN et ses Utilisations', qui couvre des Vésicules Extracellulaires (EV) innovantes avec un inhibiteur de PTEN. Ce brevet est important pour le médicament ExoPTEN de NurExone, visant à promouvoir la croissance et la régénération nerveuse après une lésion aiguë de la moelle épinière.
L'entreprise a également révélé son engagement avec Allele Capital Partners pour des services de relations avec les investisseurs, y compris des consultations sur les marchés de capitaux et la diffusion de vidéos d'entreprise sur les réseaux sociaux. L'accord initial est d'un mois à 11 000 $ par mois, avec la possibilité d'extension et une augmentation des frais à 14 500 $ lors de la cotation sur la NYSE ou le NASDAQ.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) hat die Erweiterung ihrer ExoPTEN-Patentabdeckung bekannt gegeben. Das israelische Patentamt hat eine Genehmigungsmitteilung für ein Patent mit dem Titel 'Vesikel, die einen PTEN-Inhibitor enthalten und deren Verwendung' erlassen, das innovative extrazelluläre Vesikel (EVs) mit einem PTEN-Inhibitor abdeckt. Dieses Patent ist wichtig für das ExoPTEN-Arzneimittel von NurExone, das darauf abzielt, das Wachstum und die Regeneration von Nerven nach einer akuten Rückenmarksverletzung zu fördern.
Das Unternehmen gab außerdem bekannt, dass es mit Allele Capital Partners zusammenarbeitet, um Dienstleistungen im Bereich Investor Relations anzubieten, darunter Beratung zu den Kapitalmärkten und die Verbreitung von Unternehmensvideos in sozialen Medien. Der ursprüngliche Vertrag gilt für einen Monat zu 11.000 USD pro Monat mit der Möglichkeit einer Verlängerung und einer Erhöhung der Gebühr auf 14.500 USD bei einer Listung an der NYSE oder NASDAQ.
- Expansion of ExoPTEN patent coverage in Israel
- Progress towards clinical trials and commercialization of ExoPTEN nanodrug
- Positive results from a small study in the glaucoma market reaffirming ExoPTEN's regenerative potential
- Monthly expenses of $11,000 for investor relations services, potentially increasing to $14,500
TORONTO and HAIFA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce that the Israel Patent Office recently issued a Notice of Allowance for an ExoPTEN patent, covering innovative Extracellular Vesicles (EVs) comprising a phosphatase and tensin homolog (“PTEN”) inhibitor and their application use. The Company’s ExoPTEN drug, currently under development, aims to promote nerve growth and regeneration after acute spinal cord injury by inhibiting the PTEN protein.
The patent, titled “Vesicles Comprising a PTEN Inhibitor and Uses of Same”, was originally submitted by the Technion Research and Development Foundation Ltd. (“Technion”) and Ramot at Tel Aviv University Ltd. It is the first patent licensed by NurExone from Technion and describes a fundamental element of the Company’s ExoPTEN nanodrug under development for acute spinal cord injury.
Dr. Lior Shaltiel, CEO of NurExone, explained, “This patent is part of the ExoPTEN family within our extensive IP portfolio and exclusively licensed worldwide from the Technion. We are advancing ExoPTEN, our first nanodrug towards clinical trials in humans and commercialization. Recent results of a small study for the glaucoma market reaffirm the regenerative potential of ExoPTEN, further bolstering our confidence in its therapeutic capabilities.”
Engagement of Allele Capital Partners
The Company also announces that it has entered into a consulting agreement with Allele Capital Partners, LLC ("Allele Capital") to provide investor relation services including capital markets consultation, corporate video dissemination on social media, social engagement reporting, and other related services ("Engagement"). Allele Capital is an independently owned capital markets advisory firm based in the United States. In connection with the Engagement, the Company will pay US
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Zacks and Allele engagements, including the term, fees and deliverables thereunder; the focus of the Company’s drug products; the patents safeguarding NurExone’s technology; the Company making progress using these technologies to move to commercialization of their products; and the NurExone platform technology offering novel solutions to drug companies.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate; the general market conditions; the ability to secure additional funding; the Amending Agreement being approved by the TSXV; to the Zacks and Allele engagements, having the intended impact on the Company and its business; the patents safeguarding NurExone’s technology; the Company’s drug products will have their intended benefits and effects; the Company will make progress using these technologies and move to commercialization of their products; the Company’s intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; and the NurExone platform technology will offer novel solutions to drug companies.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; protection of the Company’s intellectual property; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; the NurExone platform technology being unable to offer novel solutions to drug companies; risk that the Company will not pay the registration fees prior to the deadline or at all; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to realize upon the terms and benefits of the Zacks and Allele engagements; and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
FAQ
What is the latest patent development for NurExone Biologic Inc. (NRXBF)?
What is the purpose of NurExone's ExoPTEN drug?
Who has NurExone Biologic Inc. (NRXBF) engaged for investor relations services?
How much is NurExone Biologic Inc. (NRXBF) paying for investor relations services?
